Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016
August 15, 2016 17:02 ET
|
Hemispherx Biopharma, Inc.
The company continues to focus on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the...
Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen®
July 27, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 27, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it has reached an agreement with Avrio Biopharmaceuticals...
Hemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and Management Appointments
July 19, 2016 08:35 ET
|
Hemispherx Biopharma, Inc.
Promotes Carol Smith, Ph.D., to Manager of Quality as Part of Manufacturing Optimization Retains Step Change Pharma as Advisor to Strengthen Manufacturing and Technical Infrastructure Retains...
Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency
July 14, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 14, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) ("Hemispherx" or the “Company") today announced key elements of its strategic growth plan as well as additional...
Hemispherx Updates the Status of the Alferon® Manufacturing Facility
July 11, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 11, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) in response to various questions about the status of the work to repair damage to our Alferon®...
Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obtaining Commitments of $3.5 Million in Payments to Company
June 08, 2016 11:52 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, June 08, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) is pleased to announce that it has entered into multiple agreements and stipulations to settle all material...
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology
June 07, 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 07, 2016 (GLOBE NEWSWIRE) -- Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma (NYSE MKT:HEB) and a Professor of Pathology,...
Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
June 06, 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 06, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights...
Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm
May 31, 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 31, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for...
UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
May 24, 2016 12:25 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 24, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...